Unity Biotechnology Q4 2023 GAAP EPS $(0.28) May Not Be Comparable To $(0.77) Estimate
Unity Biotechnology Q4 2023 GAAP EPS $(0.28) May Not Be Comparable To $(0.77) Estimate
Unity Biotechnology 2023年第四季度GAAP每股收益美元（0.28美元）可能无法与估计的0.77美元（0.77美元）相提并论
Unity Biotechnology (NASDAQ:UBX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.77) by 63.64 percent. This is a 46.15 percent increase over losses of $(0.52) per share from the same period last year.
Unity Biotechnology（纳斯达克股票代码：UBX）公布的季度亏损为每股0.28美元，比分析师普遍预期的0.77美元（0.77美元）高出63.64％。这比去年同期每股亏损0.52美元（0.52美元）增长了46.15％。